• Home

  • Documents

  • Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on...
20

Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 2: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 3: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 4: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 5: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 6: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 7: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 8: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 9: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 10: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 11: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 12: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 13: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 14: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 15: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 16: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 17: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 18: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 19: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN
Page 20: Doc1 - indianjgastro.com fileSuccess story of PEG-IFN in hepatitis C and some preliminary data on PEG- IFN in hepatitis B, we undertook this open study. To study the response to PEG-IFN

HEPATITIS DELTA VIRUS (HDV)...HBV + HDV HBV P = 0.001 HBV + HDV HBV P = 0.0002 Follow-up Years Time to Event (Years) PEG IFN-aHAS MODEST BENEFIT IN HDV 6 Tolerability a Problem, Rebound

HEPATITIS DELTA VIRUS (HDV)...HBV + HDV HBV P = 0.001 HBV + HDV HBV P = 0.0002 Follow-up Years Time to Event (Years) PEG IFN-aHAS MODEST BENEFIT IN HDV 6 Tolerability a Problem, Rebound

Documents
Hepatitis C (Direct Acting Antiviral Medications for Treatment of …Direct_Acting... · who failed prior treatment with peginterferon alfa (PEG-IFN) and ribavirin (RBV) with or without

Hepatitis C (Direct Acting Antiviral Medications for Treatment of …Direct_Acting... · who failed prior treatment with peginterferon alfa (PEG-IFN) and ribavirin (RBV) with or without

Documents
Presentation - Quality of biologicals · (EPO, IFN ,IFN- 1, PEG-IFN- ... Production. Sterile filtration / Aseptic filling. DRUG PRODUCT. Drug product. production. Typical biotech

Presentation - Quality of biologicals · (EPO, IFN ,IFN- 1, PEG-IFN- ... Production. Sterile filtration / Aseptic filling. DRUG PRODUCT. Drug product. production. Typical biotech

Documents
Gebelik Dışı Özel Durumlarda +++ -/+ IFN / Peg-IFN +++ + 23 HIV/ HBV Koenfeksiyonu HIV/HBV koenfekte tüm olgulara CD4 sayısına bakılmaksızın ART başlanması önerilir ART

Gebelik Dışı Özel Durumlarda +++ -/+ IFN / Peg-IFN +++ + 23 HIV/ HBV Koenfeksiyonu HIV/HBV koenfekte tüm olgulara CD4 sayısına bakılmaksızın ART başlanması önerilir ART

Documents
Treatment of chronic hepatitis C virus infection in Japan ... · Treatment of chronic hepatitis C virus infection in Japan: ... bination with peg-interferon and ribavirin is expected

Treatment of chronic hepatitis C virus infection in Japan ... · Treatment of chronic hepatitis C virus infection in Japan: ... bination with peg-interferon and ribavirin is expected

Documents
Caso Clínico. Hepatitis B crónica HBe Ag + 1998 - Diagnostico HB Crónica HBe Ag +. Realiza Tratamiento con IFN. Sin Respuesta. 1999 - Inicia Lamivudine

Caso Clínico. Hepatitis B crónica HBe Ag + 1998 - Diagnostico HB Crónica HBe Ag +. Realiza Tratamiento con IFN. Sin Respuesta. 1999 - Inicia Lamivudine

Documents
Dossier zur Nutzenbewertung gemäß § 35a SGB V · Polyethylenglykol (PEG) gekoppeltes IFN (PEG-IFN), sowie NA wie Entecavir (ETV), TDF, Lamivudin, Telbivudin oder Adefovir zugelassen

Dossier zur Nutzenbewertung gemäß § 35a SGB V · Polyethylenglykol (PEG) gekoppeltes IFN (PEG-IFN), sowie NA wie Entecavir (ETV), TDF, Lamivudin, Telbivudin oder Adefovir zugelassen

Documents
The Changing Face of Hepatitis C Treatment · 2016. 5. 6. · TMC435 (QD oral HCV NS3/4A PI) + Peg-IFN α-2a/RBV (PR) • Very high SVR in PR group, European study, low BMI • For

The Changing Face of Hepatitis C Treatment · 2016. 5. 6. · TMC435 (QD oral HCV NS3/4A PI) + Peg-IFN α-2a/RBV (PR) • Very high SVR in PR group, European study, low BMI • For

Documents
La Lettre de linfectiologue Étude C212 : simeprevir + PEG-IFN/RBV chez les co-infectés VIH-VHC GT1 (1) Critère principal : RVS12, sécurité et tolérance

La Lettre de linfectiologue Étude C212 : simeprevir + PEG-IFN/RBV chez les co-infectés VIH-VHC GT1 (1) Critère principal : RVS12, sécurité et tolérance

Documents
Rekombinante Wirkstoffe - user.uni-frankfurt.deuser.uni-frankfurt.de/~dingerma/Podcast/Rekombinante_Wirkstoffe_WS... · Peg-Interferone alfa Indikation: 1. Chronische Hepatitis B:

Rekombinante Wirkstoffe - user.uni-frankfurt.deuser.uni-frankfurt.de/~dingerma/Podcast/Rekombinante_Wirkstoffe_WS... · Peg-Interferone alfa Indikation: 1. Chronische Hepatitis B:

Documents
Pegasys, INN-peginterferon alfa-2a · Pegasys (pegylated interferon alpha 2a, PEG-IFN α2a) was approved in 2002 for the treatment of chronic hepatitis B (CHB) and chronic hepatitis

Pegasys, INN-peginterferon alfa-2a · Pegasys (pegylated interferon alpha 2a, PEG-IFN α2a) was approved in 2002 for the treatment of chronic hepatitis B (CHB) and chronic hepatitis

Documents
Treatment of hepatitis B - American College of ...s3.gi.org/wp-content/uploads/2015/06/15ACG_Hepatitis_School_Boston...Entecavir Telbivudine* Peg-IFN alfa-2a *HBV DNA must be undetectable

Treatment of hepatitis B - American College of ...s3.gi.org/wp-content/uploads/2015/06/15ACG_Hepatitis_School_Boston...Entecavir Telbivudine* Peg-IFN alfa-2a *HBV DNA must be undetectable

Documents
Yan Etki Yonetimi - VHSD · 25 Trombositopeni – Doz modifikasyon önerileri PEG-IFN-α Trombosit sayısı(sayı/mm3) Öneri 2a

Yan Etki Yonetimi - VHSD · 25 Trombositopeni – Doz modifikasyon önerileri PEG-IFN-α Trombosit sayısı(sayı/mm3) Öneri 2a

Documents
QUEST 1 et 2 : simeprevir + PEG-IFN/RBV chez patients naïfs G1 (1) Etudes de phase III, randomisées, multicentriques, double aveugle, comparant SMV 150

QUEST 1 et 2 : simeprevir + PEG-IFN/RBV chez patients naïfs G1 (1) Etudes de phase III, randomisées, multicentriques, double aveugle, comparant SMV 150

Documents
This drawing illustrates the context of the existing ... filew.l w.l w.l w.l w.l w.l w.l w.l w.l w.l w.l peg peg peg peg peg peg peg peg peg peg peg peg peg tp tp tp tp tp tp tp tp

This drawing illustrates the context of the existing ... filew.l w.l w.l w.l w.l w.l w.l w.l w.l w.l w.l peg peg peg peg peg peg peg peg peg peg peg peg peg tp tp tp tp tp tp tp tp

Documents
Evaluación económica del PAM en el tratamiento de la hepatitis … · 2010-11-25 · PEG-IFN alfa 2a más RBV: Tasas de RVS en estudios clínicos y en práctica clínica PEGASYS®

Evaluación económica del PAM en el tratamiento de la hepatitis … · 2010-11-25 · PEG-IFN alfa 2a más RBV: Tasas de RVS en estudios clínicos y en práctica clínica PEGASYS®

Documents
2nd wave IFN-based triple therapy for HCV … wave IFN-based triple therapy for HCV genotype 1: Simeprevir, Faldaprevir and Sofosbuvir. Paris Hepatitis Conference Pr Tarik Asselah

2nd wave IFN-based triple therapy for HCV … wave IFN-based triple therapy for HCV genotype 1: Simeprevir, Faldaprevir and Sofosbuvir. Paris Hepatitis Conference Pr Tarik Asselah

Documents
VeriPlexTM Human Interferon 9-Plex ELISA Kit - PBL Assay Sci · hepatitis B and hepatitis C infections. Additionally, IFN-α is known to have significant biological activity in inhibition

VeriPlexTM Human Interferon 9-Plex ELISA Kit - PBL Assay Sci · hepatitis B and hepatitis C infections. Additionally, IFN-α is known to have significant biological activity in inhibition

Documents
Why do I include peg-IFN in Hepatitis C treatment - genotype 1 Bendor July 2014 [Lecture seule].pdfInternational Liver Congress 2013, Amsterdam Treatment With Sofosbuvir+ Peginterferon+

Why do I include peg-IFN in Hepatitis C treatment - genotype 1 Bendor July 2014 [Lecture seule].pdfInternational Liver Congress 2013, Amsterdam Treatment With Sofosbuvir+ Peginterferon+

Documents
New Treatments for Hepatitis C Virus - HCV Action · complications kill 350,000 people annually. Currently, the standard of care is injectable peg-interferon (PEG-IFN) used in combination

New Treatments for Hepatitis C Virus - HCV Action · complications kill 350,000 people annually. Currently, the standard of care is injectable peg-interferon (PEG-IFN) used in combination

Documents
PEG INTRON® Pen - POMioni.pom.go.id/sites/default/files/obat_baru/Pegintron.pdfIn PEG-INTRON® monotherapy trial, a total of 916 naive chronic hepatitis C patients were treated with

PEG INTRON® Pen - POMioni.pom.go.id/sites/default/files/obat_baru/Pegintron.pdfIn PEG-INTRON® monotherapy trial, a total of 916 naive chronic hepatitis C patients were treated with

Documents
Challenges of Clinical Research on Hepatocellular Carcinoma · 2016. 8. 3. · hepatitis C virus by interferon (IFN) therapy for chronic hepatitis C. However, it is unclear whether

Challenges of Clinical Research on Hepatocellular Carcinoma · 2016. 8. 3. · hepatitis C virus by interferon (IFN) therapy for chronic hepatitis C. However, it is unclear whether

Documents
Hepatitis C Therapie 2017 - PEG-Symposien · Hepatitis C Chronische Hepatitis C 20-30% in 20-30 Jahren 1-5% pro Jahr Viruselimination Natürlicher Verlauf der chronischen Hepatitis

Hepatitis C Therapie 2017 - PEG-Symposien · Hepatitis C Chronische Hepatitis C 20-30% in 20-30 Jahren 1-5% pro Jahr Viruselimination Natürlicher Verlauf der chronischen Hepatitis

Documents
Jorge Daruich Hospital de Clínicas San Martín Universidad de Buenos Aires Hepatitis C Resultados terapéuticos PEG IFN 2a 40 KD 12º Reunión Anual Unidades

Jorge Daruich Hospital de Clínicas San Martín Universidad de Buenos Aires Hepatitis C Resultados terapéuticos PEG IFN 2a 40 KD 12º Reunión Anual Unidades

Documents
Overview on latest data on IFN-sparing and IFN-free ...regist2.virology-education.com/2014/10coinf/32_Ingiliz.pdf · 10th HIV and hepatitis coinfection workshop June 2014 ... at Week

Overview on latest data on IFN-sparing and IFN-free ...regist2.virology-education.com/2014/10coinf/32_Ingiliz.pdf · 10th HIV and hepatitis coinfection workshop June 2014 ... at Week

Documents
NOVÁ ANTIVIROTIKA V LÉČBĚ HCV INFEKCEBelerofon Albuferon Locteron IFN typu III Peg-IFN-lambda (Peg-rIL-29) IFN-lambda-indukovaná protivirová aktivita přes podobnou signální

NOVÁ ANTIVIROTIKA V LÉČBĚ HCV INFEKCEBelerofon Albuferon Locteron IFN typu III Peg-IFN-lambda (Peg-rIL-29) IFN-lambda-indukovaná protivirová aktivita přes podobnou signální

Documents
Therapieoptionen Hepatitis B - medunikkh.de · HBsAg positiv GPT HBV-DNA. Hepatitis B – Therapieerfolg PEG Interferon Ruhr-Universität Bochum Knappschaftskrankenhaus AASLD guidelines

Therapieoptionen Hepatitis B - medunikkh.de · HBsAg positiv GPT HBV-DNA. Hepatitis B – Therapieerfolg PEG Interferon Ruhr-Universität Bochum Knappschaftskrankenhaus AASLD guidelines

Documents
Pegylated IFN-α suppresses hepatitis C virus by promoting ... · Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway Wei-Liang Liua,b, Hung-Chih Yangc,d,

Pegylated IFN-α suppresses hepatitis C virus by promoting ... · Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway Wei-Liang Liua,b, Hung-Chih Yangc,d,

Documents
Therapeutic Class Overview Hepatitis C Polymerase Inhibitors · o The standard drug regimen for chronic hepatitis C requires 24 to 48 weeks of treatment, with self-injections of peg

Therapeutic Class Overview Hepatitis C Polymerase Inhibitors · o The standard drug regimen for chronic hepatitis C requires 24 to 48 weeks of treatment, with self-injections of peg

Documents
Inhibition of Hepatitis C Virus Replication by IFN-Mediated

Inhibition of Hepatitis C Virus Replication by IFN-Mediated

Documents